Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research ...

Equities research analysts at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) ...

In CHI, the beta cells in the pancreas do not function ... its Boehringer Ingelheim-partnered dual glucagon/GLP-1 receptor agonist survodutide has been awarded breakthrough status by the FDA ...

Many individuals are told that managing type 2 diabetes is simply a matter of controlling blood sugar. As long as glucos ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), ... Islet Transplantation With Blood Vessel Cells Shows Promise to ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

The authors say this may be because it has a longer half-life than other drugs and is nonselective, which means it can bind to any beta receptors. In the study, hypoglycemia was also more likely ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...